Biocompatible Smart Nanovectors for the chemoterapy treatment of prostate cancer
In developed countries cancer is the second most important cause of death. Since 1 in 4 Canadians will die of the disease and 1 in 8 men will be diagnosed with prostate cancer (PC), advanced chemotherapeutic treatments represent an important strategy to reduce cancer deaths without compromising a patients quality of life during and post-treatment. To this end, we will couple already established anticancer drugs (e.g. cisplatin) with innovative delivery strategies (so-called nanovectors) to more selectively deliver multiple anti-cancer drugs to cancer cells to trigger cell apoptosis and block tumor spreading. Biocompatible nanovectors labeled with a fluorescent marker will be coated with a peptide to direct the nanovector to the tumor. After loading the nanovectors with established platinum anticancer drugs, a research tool developed in Dr. Gailer’s lab (SEC-ICP-AES) will be used to determine the stability and the potential release of the platinum-drugs from the nanovector complex at physiological pH. Thereafter, the same research tool will be employed to observe the stability of those nanovector-platinum drug complexes in human blood plasma. Taken together, the proposed investigations are intended to significantly improve the targeted delivery of established anti-cancer drugs to the cancer target to develop more effective treatments against PC.
Voir la description complète du projetJurgen Gailer
University of Pisa
Life Sciences
Education
University of Calgary
Globalink Research Award